SCHEMBL3424201

SCHEMBL3424201

CCOC(=O)c1ccc2[nH]c(-c3cc(-c4cc(C)c(O)c(C)c4)nnc3OC)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.42
MMP13 P45452 3/20 0.41
MMP2 P08253 2/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40
TUBB6 Q9BUF5 1/20 0.40
TUBB2B Q9BVA1 1/20 0.40
TUBB1 Q9H4B7 1/20 0.40
PKN1 Q16512 1/20 0.40
PKN2 Q16513 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3424712 0.89 PKN1 (0.51) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL3428216 0.88 F2 (0.42) HRH3F2F10PLGPLAU
SCHEMBL3425389 0.84 HRH3 (0.46) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL1751045 0.80 KDM4E (0.47) KDM4EALDH1A1RAB9AHPGDNPC1
SCHEMBL7848024 0.71 HRH3 (0.55) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL1260807 0.71 TUBB4A (0.72) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL3425872 0.71 PKN1 (0.51) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL8212523 0.71 HRH3 (0.52) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL15058016 0.71 FFAR1 (0.54) HRH3MMP13MMP2TUBB4ATUBB
SCHEMBL3427280 0.70 MAPK1 (0.48) MMP13MMP2TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753743-B1 PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS DEUTSCHLAND (DE) 2015-03-04 EP disclosed
US-7709466-B2 Pyridazinone derivatives, methods for their production and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088041-A1 PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS GSK3B, GSK3A, PDXK HRH3 932/4885MMP13 2309/4885MMP2 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.